191 related articles for article (PubMed ID: 10992445)
1. Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.
Munson EL; Du Chateau BK; Jobe DA; Lovrich SD; Callister SM; Schell RF
Infect Immun; 2000 Oct; 68(10):5496-501. PubMed ID: 10992445
[TBL] [Abstract][Full Text] [Related]
2. Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.
Munson EL; Du Chateau BK; Jensen JR; Callister SM; DeCoster DJ; Schell RF
Clin Diagn Lab Immunol; 2002 Sep; 9(5):1095-101. PubMed ID: 12204965
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody.
Remington MC; Munson EL; Callister SM; Molitor ML; Christopherson JA; DeCoster DJ; Lovrich SD; Schell RF
Infect Immun; 2001 Jul; 69(7):4268-75. PubMed ID: 11401963
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro.
Munson EL; Nardelli DT; Luk KH; Remington MC; Callister SM; Schell RF
Clin Vaccine Immunol; 2006 Jan; 13(1):19-25. PubMed ID: 16425995
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the production of anti-OspA borreliacidal antibody with T cells from hamsters vaccinated against Borrelia burgdorferi.
Jensen JR; Du Chateau BK; Munson EL; Callister SM; Schell RF
Infect Immun; 1998 Apr; 66(4):1507-12. PubMed ID: 9529074
[TBL] [Abstract][Full Text] [Related]
6. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi.
Ma J; Bulger PA; Davis DR; Perilli-Palmer B; Bedore DA; Kensil CR; Young EM; Hung CH; Seals JR; Pavia CS
Vaccine; 1994 Aug; 12(10):925-32. PubMed ID: 7975834
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine.
Padilla ML; Callister SM; Schell RF; Bryant GL; Jobe DA; Lovrich SD; DuChateau BK; Jensen JR
J Infect Dis; 1996 Oct; 174(4):739-46. PubMed ID: 8843211
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
[TBL] [Abstract][Full Text] [Related]
9. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
10. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
[TBL] [Abstract][Full Text] [Related]
11. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
12. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH
Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test.
Callister SM; Schell RF; Case KL; Lovrich SD; Day SP
J Infect Dis; 1993 Jan; 167(1):158-64. PubMed ID: 8418162
[TBL] [Abstract][Full Text] [Related]
14. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
[TBL] [Abstract][Full Text] [Related]
15. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
16. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.
Johnson BJ; Sviat SL; Happ CM; Dunn JJ; Frantz JC; Mayer LW; Piesman J
Vaccine; 1995 Aug; 13(12):1086-94. PubMed ID: 7491816
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes.
Federizon J; Frye A; Huang WC; Hart TM; He X; Beltran C; Marcinkiewicz AL; Mainprize IL; Wills MKB; Lin YP; Lovell JF
Vaccine; 2020 Jan; 38(4):942-950. PubMed ID: 31727504
[TBL] [Abstract][Full Text] [Related]
18. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.
Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA
Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289
[TBL] [Abstract][Full Text] [Related]
19. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.
Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E
Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431
[TBL] [Abstract][Full Text] [Related]
20. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
Luke CJ; Carner K; Liang X; Barbour AG
J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
